IDEAYA Biosciences (IDYA) Research & Development (2018 - 2026)

IDEAYA Biosciences has reported Research & Development for 9 years, with the latest figure at $95.7 million in Q1 2026.

• Quarterly Research & Development rose 35.04% year-over-year to $95.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $290.0 million (up 82.02% YoY) and the FY2025 annual result came in at $314.7 million, up 277.24% from the prior year.
• Research & Development rose to $95.7 million in Q1 2026 per IDYA's latest filing, from $86.6 million in the prior quarter.
• Over five years, Research & Development peaked at $95.7 million in Q1 2026 and troughed at -$45.1 million in Q4 2023.
• A 5-year average of $33.8 million and a median of $29.2 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 271.4% in 2022, then soared 633.77% in 2025.
• Over 5 years, Research & Development stood at -$27.6 million in 2022, then tumbled by 63.32% to -$45.1 million in 2023, then surged by 126.17% to $11.8 million in 2024, then jumped by 633.77% to $86.6 million in 2025, then grew by 10.54% to $95.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $95.7 million, $86.6 million, and $33.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.